Compugen Ltd.

Equities

CGEN

IL0010852080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
2.15 ^USD	+2.87%		-1.83%	+8.59%

May. 30	Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	CI
May. 20	Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating	MT

Compugen Ltd. Announces Board Changes

February 24, 2022 at 07:00 am EST

Compugen Ltd. announced the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb, to its Board of Directors effective March 1, 2022. In addition, the company announced that Dr. Jean-Pierre Bizzari will retire from its Board of Directors.

Latest news about Compugen Ltd.

Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	May. 30	CI
Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating	May. 20	MT
Transcript : Compugen Ltd., Q1 2024 Earnings Call, May 20, 2024	May. 20
Earnings Flash (CGEN) COMPUGEN Reports Q1 Revenue $2.6M, vs. Street Est of $1.2M	May. 20	MT
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 20	CI
Compugen Names David Silberman CFO	May. 15	MT
Compugen Ltd. Announces CFO Changes, Effective August 15, 2024	May. 15	CI
Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating	Mar. 08	MT
Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Earnings Flash (CGEN) COMPUGEN Reports Q4 Revenue $33.5M	Mar. 05	MT
Earnings Flash (CGEN) COMPUGEN Posts Q4 EPS $0.11	Mar. 05	MT
Earnings Flash (CW9) COMPUGEN Posts Q4 EPS $0.11	Mar. 05	MT
Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05	CI
Compugen Ltd. Announces Executive Changes	Feb. 15	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Dec. 19	MT
Sector Update: Health Care	Dec. 19	MT
Looming Inflation Data Stifle US Equity Futures Pre-Bell	Dec. 19	MT
Exchange-Traded Funds, US Equities Rise Pre-Bell Tuesday as Investors Continue to Hope for Federal Reserve Rate Cuts Soon	Dec. 19	MT
Gilead Sciences, Compugen Sign Exclusive Licensing Deal for Pre-Clinical Immunotherapy Program; Compugen Shares Soar	Dec. 19	MT
Transcript : Compugen Ltd. - Special Call	Dec. 19
Top Midday Gainers	Dec. 19	MT
Top Premarket Gainers	Dec. 19	MT
Compugen Will Be Eligible to Receive $10 Million Milestone Payment Upon Dosing of First Patient in Astrazeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer	Dec. 19	CI
Gilead Sciences, Inc. and Compugen Ltd. Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program	Dec. 19	CI
Transcript : Compugen Ltd., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07

Chart Compugen Ltd.

Duration

Period

More charts

Company Profile

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Sector

Biotechnology & Medical Research

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Compugen Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.15 USD

Average target price

5 USD

Spread / Average Target

+132.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COMPUGEN LTD.	+8.59%	187M
MODERNA, INC.	+55.55%	59.34B
LONZA GROUP AG	+43.17%	40.24B
IQVIA HOLDINGS INC.	-4.71%	39.88B
CELLTRION, INC.	-5.56%	28.55B
ICON PUBLIC LIMITED COMPANY	+13.76%	27.26B
ALNYLAM PHARMACEUTICALS, INC.	-22.00%	19.23B
MEDPACE HOLDINGS, INC.	+31.50%	12.61B
BIO-TECHNE CORPORATION	+2.16%	12.49B
UNITED THERAPEUTICS CORPORATION	+25.70%	12.28B

Other Biotechnology & Medical Research